Diagnosis and management of tickborne rickettsial diseases

Rocky mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis - United States a practical guide for health care and public health professionals

Holly M. Biggs, Casey Barton Behravesh, Kristy K. Bradley, F. Scott Dahlgren, Naomi A. Drexler, J. Stephen Dumler, Scott M. Folk, Cecilia Y. Kato, R. Ryan Lash, Michael L. Levin, Robert F. Massung, Robert B. Nadelman, William L. Nicholson, Christopher D. Paddock, Bobbi S. Pritt, Marc S. Traeger

Research output: Contribution to journalArticle

Abstract

Tickborne rickettsial diseases continue to cause severe illness and death in otherwise healthy adults and children, despite the availability of low-cost, effective antibacterial therapy. Recognition early in the clinical course is critical because this is the period when antibacterial therapy is most effective. Early signs and symptoms of these illnesses are nonspecific or mimic other illnesses, which can make diagnosis challenging. Previously undescribed tickborne rickettsial diseases continue to be recognized, and since 2004, three additional agents have been described as causes of human disease in the United States: Rickettsia parkeri, Ehrlichia muris-like agent, and Rickettsia species 364D. This report updates the 2006 CDC recommendations on the diagnosis and management of tickborne rickettsial diseases in the United States and includes information on the practical aspects of epidemiology, clinical assessment, treatment, laboratory diagnosis, and prevention of tickborne rickettsial diseases. The CDC Rickettsial Zoonoses Branch, in consultation with external clinical and academic specialists and public health professionals, developed this report to assist health care providers and public health professionals to 1) recognize key epidemiologic features and clinical manifestations of tickborne rickettsial diseases, 2) recognize that doxycycline is the treatment of choice for suspected tickborne rickettsial diseases in adults and children, 3) understand that early empiric antibacterial therapy can prevent severe disease and death, 4) request the appropriate confirmatory diagnostic tests and understand their usefulness and limitations, and 5) report probable and confirmed cases of tickborne rickettsial diseases to public health authorities.

Original languageEnglish (US)
Pages (from-to)1-44
Number of pages44
JournalMMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control
Volume65
Issue number2
DOIs
StatePublished - 2016
Externally publishedYes

Fingerprint

Rocky Mountain Spotted Fever
Anaplasmosis
Ehrlichiosis
health professionals
Fever
Public Health
public health
health care
Disease
Delivery of Health Care
management
Group
Rickettsia
illness
Centers for Disease Control and Prevention (U.S.)
Ehrlichia
death
Therapeutics
empirics
cause

ASJC Scopus subject areas

  • Epidemiology
  • Health(social science)
  • Medicine(all)
  • Health, Toxicology and Mutagenesis
  • Health Information Management

Cite this

Diagnosis and management of tickborne rickettsial diseases : Rocky mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis - United States a practical guide for health care and public health professionals. / Biggs, Holly M.; Behravesh, Casey Barton; Bradley, Kristy K.; Dahlgren, F. Scott; Drexler, Naomi A.; Dumler, J. Stephen; Folk, Scott M.; Kato, Cecilia Y.; Lash, R. Ryan; Levin, Michael L.; Massung, Robert F.; Nadelman, Robert B.; Nicholson, William L.; Paddock, Christopher D.; Pritt, Bobbi S.; Traeger, Marc S.

In: MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control, Vol. 65, No. 2, 2016, p. 1-44.

Research output: Contribution to journalArticle

Biggs, Holly M. ; Behravesh, Casey Barton ; Bradley, Kristy K. ; Dahlgren, F. Scott ; Drexler, Naomi A. ; Dumler, J. Stephen ; Folk, Scott M. ; Kato, Cecilia Y. ; Lash, R. Ryan ; Levin, Michael L. ; Massung, Robert F. ; Nadelman, Robert B. ; Nicholson, William L. ; Paddock, Christopher D. ; Pritt, Bobbi S. ; Traeger, Marc S. / Diagnosis and management of tickborne rickettsial diseases : Rocky mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis - United States a practical guide for health care and public health professionals. In: MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 2016 ; Vol. 65, No. 2. pp. 1-44.
@article{b88973f59b5044b5b56f3e53361887e2,
title = "Diagnosis and management of tickborne rickettsial diseases: Rocky mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis - United States a practical guide for health care and public health professionals",
abstract = "Tickborne rickettsial diseases continue to cause severe illness and death in otherwise healthy adults and children, despite the availability of low-cost, effective antibacterial therapy. Recognition early in the clinical course is critical because this is the period when antibacterial therapy is most effective. Early signs and symptoms of these illnesses are nonspecific or mimic other illnesses, which can make diagnosis challenging. Previously undescribed tickborne rickettsial diseases continue to be recognized, and since 2004, three additional agents have been described as causes of human disease in the United States: Rickettsia parkeri, Ehrlichia muris-like agent, and Rickettsia species 364D. This report updates the 2006 CDC recommendations on the diagnosis and management of tickborne rickettsial diseases in the United States and includes information on the practical aspects of epidemiology, clinical assessment, treatment, laboratory diagnosis, and prevention of tickborne rickettsial diseases. The CDC Rickettsial Zoonoses Branch, in consultation with external clinical and academic specialists and public health professionals, developed this report to assist health care providers and public health professionals to 1) recognize key epidemiologic features and clinical manifestations of tickborne rickettsial diseases, 2) recognize that doxycycline is the treatment of choice for suspected tickborne rickettsial diseases in adults and children, 3) understand that early empiric antibacterial therapy can prevent severe disease and death, 4) request the appropriate confirmatory diagnostic tests and understand their usefulness and limitations, and 5) report probable and confirmed cases of tickborne rickettsial diseases to public health authorities.",
author = "Biggs, {Holly M.} and Behravesh, {Casey Barton} and Bradley, {Kristy K.} and Dahlgren, {F. Scott} and Drexler, {Naomi A.} and Dumler, {J. Stephen} and Folk, {Scott M.} and Kato, {Cecilia Y.} and Lash, {R. Ryan} and Levin, {Michael L.} and Massung, {Robert F.} and Nadelman, {Robert B.} and Nicholson, {William L.} and Paddock, {Christopher D.} and Pritt, {Bobbi S.} and Traeger, {Marc S.}",
year = "2016",
doi = "10.15585/mmwr.rr6502a1",
language = "English (US)",
volume = "65",
pages = "1--44",
journal = "MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control",
issn = "1057-5987",
publisher = "Public Health Services, US Dept of Health and Human Services",
number = "2",

}

TY - JOUR

T1 - Diagnosis and management of tickborne rickettsial diseases

T2 - Rocky mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis - United States a practical guide for health care and public health professionals

AU - Biggs, Holly M.

AU - Behravesh, Casey Barton

AU - Bradley, Kristy K.

AU - Dahlgren, F. Scott

AU - Drexler, Naomi A.

AU - Dumler, J. Stephen

AU - Folk, Scott M.

AU - Kato, Cecilia Y.

AU - Lash, R. Ryan

AU - Levin, Michael L.

AU - Massung, Robert F.

AU - Nadelman, Robert B.

AU - Nicholson, William L.

AU - Paddock, Christopher D.

AU - Pritt, Bobbi S.

AU - Traeger, Marc S.

PY - 2016

Y1 - 2016

N2 - Tickborne rickettsial diseases continue to cause severe illness and death in otherwise healthy adults and children, despite the availability of low-cost, effective antibacterial therapy. Recognition early in the clinical course is critical because this is the period when antibacterial therapy is most effective. Early signs and symptoms of these illnesses are nonspecific or mimic other illnesses, which can make diagnosis challenging. Previously undescribed tickborne rickettsial diseases continue to be recognized, and since 2004, three additional agents have been described as causes of human disease in the United States: Rickettsia parkeri, Ehrlichia muris-like agent, and Rickettsia species 364D. This report updates the 2006 CDC recommendations on the diagnosis and management of tickborne rickettsial diseases in the United States and includes information on the practical aspects of epidemiology, clinical assessment, treatment, laboratory diagnosis, and prevention of tickborne rickettsial diseases. The CDC Rickettsial Zoonoses Branch, in consultation with external clinical and academic specialists and public health professionals, developed this report to assist health care providers and public health professionals to 1) recognize key epidemiologic features and clinical manifestations of tickborne rickettsial diseases, 2) recognize that doxycycline is the treatment of choice for suspected tickborne rickettsial diseases in adults and children, 3) understand that early empiric antibacterial therapy can prevent severe disease and death, 4) request the appropriate confirmatory diagnostic tests and understand their usefulness and limitations, and 5) report probable and confirmed cases of tickborne rickettsial diseases to public health authorities.

AB - Tickborne rickettsial diseases continue to cause severe illness and death in otherwise healthy adults and children, despite the availability of low-cost, effective antibacterial therapy. Recognition early in the clinical course is critical because this is the period when antibacterial therapy is most effective. Early signs and symptoms of these illnesses are nonspecific or mimic other illnesses, which can make diagnosis challenging. Previously undescribed tickborne rickettsial diseases continue to be recognized, and since 2004, three additional agents have been described as causes of human disease in the United States: Rickettsia parkeri, Ehrlichia muris-like agent, and Rickettsia species 364D. This report updates the 2006 CDC recommendations on the diagnosis and management of tickborne rickettsial diseases in the United States and includes information on the practical aspects of epidemiology, clinical assessment, treatment, laboratory diagnosis, and prevention of tickborne rickettsial diseases. The CDC Rickettsial Zoonoses Branch, in consultation with external clinical and academic specialists and public health professionals, developed this report to assist health care providers and public health professionals to 1) recognize key epidemiologic features and clinical manifestations of tickborne rickettsial diseases, 2) recognize that doxycycline is the treatment of choice for suspected tickborne rickettsial diseases in adults and children, 3) understand that early empiric antibacterial therapy can prevent severe disease and death, 4) request the appropriate confirmatory diagnostic tests and understand their usefulness and limitations, and 5) report probable and confirmed cases of tickborne rickettsial diseases to public health authorities.

UR - http://www.scopus.com/inward/record.url?scp=84981340607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981340607&partnerID=8YFLogxK

U2 - 10.15585/mmwr.rr6502a1

DO - 10.15585/mmwr.rr6502a1

M3 - Article

VL - 65

SP - 1

EP - 44

JO - MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control

JF - MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control

SN - 1057-5987

IS - 2

ER -